PRIA Logo™
LouisianaSB 432026 Regular SessionSenateWALLET

HEALTH SERVICES: Provides relative to psychedelic-assisted therapy. (8/1/26) (EN INCREASE GF EX See Note)

Sponsored By: Patrick McMath (Republican)

Became Law

Health and Welfare

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 1 benefits, 1 costs, 1 mixed.

Louisiana helps patients join psychedelic studies

Beginning August 1, 2026, Louisiana’s health department runs a program supporting psychedelic therapy research and keeps a registry of participating centers. Centers may use local human service agencies to identify people with opioid addiction, related substance use disorders, or treatment-resistant neurological or mental health conditions. Therapy combines controlled clinical dosing with trauma-informed counseling before and after dosing; covered medicines include ibogaine, MDMA, psilocybin, and related compounds. Centers must work with parishes to use opioid settlement money to enroll eligible residents of those parishes. Settlement money can also support trial-enabling studies and, where feasible, help match outside funding; the department may accept federal funds, grants, gifts, and donations. A state contact coordinates with federal agencies and other states. The law sets no funding amount and guarantees neither enrollment nor treatment.

Research centers face new study requirements

Beginning August 1, 2026, participating academic health centers must keep records showing compliance with state and federal study rules. Studies need an authorized federal pathway, on-site facilities, liability insurance, required controlled-drug registrations, and ethics board approval. Required plans cover study design, patient selection, follow-up, drug sources, dosing, staffing, monitoring, discharge, and transportation. Centers must document drug storage, handling, tracking, disposal, and accountability for violations. Safety plans must cover screening, emergencies, adverse-event reporting deadlines, and rules for pausing or stopping studies. Centers also need plans for clinician qualifications, training, supervision, treatment standards, participant safeguards, and complaints. Centers report to the health department annually by January 1; the department specifies required data and reports to lawmakers by March 1. These duties apply to centers, not patients.

Drug research partnerships must share sales

Beginning August 1, 2026, academic health centers may partner with drug developers to study ibogaine and other psychedelic medicines. These partnerships can seek FDA approval for opioid addiction, related substance use disorders, or other conditions where treatment shows effectiveness. They may file investigational drug applications, seek breakthrough therapy status, and coordinate trials with other states. An out-of-state partner must have filed an investigational drug application and requested breakthrough therapy status for ibogaine. Revenue-sharing rules cover intellectual property and commercial rights from partnership trials, including patents, licenses, data, and treatment methods. Louisiana receives a royalty of at least 2.5% of net sales during trial funding and later commercialization; partners divide the remainder under their written agreement. The law does not direct this money to households.

Sponsors & Cosponsors

Sponsor

  • Patrick McMath

    Republican • Senate

Cosponsors

  • Adam Bass

    Republican • Senate

  • Beth Mizell

    Republican • Senate

  • Blake Miguez

    Republican • Senate

  • Bob Hensgens

    Republican • Senate

  • Caleb Kleinpeter

    Republican • Senate

  • Cameron Henry

    Republican • Senate

  • Gary Carter

    Democratic • Senate

  • Gerald Boudreaux

    Democratic • Senate

  • Gregory A. Miller

    Republican • Senate

  • Heather Cloud

    Republican • Senate

  • Jay Luneau

    Democratic • Senate

  • Jimmy Harris

    Democratic • Senate

  • Katrina R. Jackson-Andrews

    Democratic • Senate

  • Michael "Big Mike" Fesi

    Republican • Senate

  • Patrick Connick

    Republican • Senate

  • Rick Edmonds

    Republican • Senate

  • Royce Duplessis

    Democratic • Senate

  • Sam Jenkins

    Democratic • Senate

  • Sidney Barthelemy II

    Democratic • Senate

Roll Call Votes

All Roll Calls

Yes: 275 • No: 0

House vote • 5/31/2026

Conference Committee Report read, roll called, yeas 97, nays 0. The Conference Committee Report was adopted.

Yes: 97 • No: 0

Senate vote • 5/29/2026

Conference Committee Report read; adopted by a vote of 35 yeas and 0 nays.

Yes: 35 • No: 0

House vote • 5/7/2026

Read third time by title, amended, roll called on final passage, yeas 97, nays 0. Finally passed, ordered to the Senate.

Yes: 97 • No: 0

House vote • 4/28/2026

Reported with amendments

Yes: 9 • No: 0

Senate vote • 4/15/2026

Senate floor amendments read and adopted. Read by title and passed by a vote of 37 yeas and 0 nays; ordered reengrossed and sent to the House. Motion to reconsider tabled.

Yes: 37 • No: 0

Actions Timeline

  1. Becomes Act No. 956 without the Governor's signature.

    6/23/2026Senate

  2. Effective date 8/1/2026.

    6/23/2026Senate

  3. Enrolled. Signed by the President of the Senate.

    6/1/2026Senate

  4. Signed by the Speaker of the House.

    6/1/2026House

  5. Sent to the Governor by the Secretary of the Senate.

    6/1/2026Senate

  6. Conference Committee Report read, roll called, yeas 97, nays 0. The Conference Committee Report was adopted.

    5/31/2026House

  7. Notice House adopted the Conference Committee Report.

    5/31/2026Senate

  8. Conference Committee Report read; adopted by a vote of 35 yeas and 0 nays.

    5/29/2026Senate

  9. Notice of Senate adoption of Conference Committee Report.

    5/29/2026House

  10. Scheduled for floor debate on 05/31/2026.

    5/29/2026House

  11. Scheduled for floor debate on 05/29/2026.

    5/27/2026House

  12. Conference Committee report received. Lies over under the rules.

    5/26/2026House

  13. Conference committee report received.

    5/25/2026Senate

  14. Notice of Senate conferees appointed.

    5/25/2026House

  15. Senate conference committee members appointed: McMath, Luneau, and Owen.

    5/21/2026Senate

  16. House conferees appointed: Riser, Miller, and Egan.

    5/19/2026House

  17. Notice House Conference Committee members appointed.

    5/19/2026Senate

  18. Notice of Senate rejecting House amendments.

    5/18/2026House

  19. Received from the House with amendments.

    5/11/2026Senate

  20. Read third time by title, amended, roll called on final passage, yeas 97, nays 0. Finally passed, ordered to the Senate.

    5/7/2026House

  21. Scheduled for floor debate on 05/07/2026.

    5/6/2026House

  22. Read by title, amended, passed to 3rd reading.

    5/5/2026House

  23. Reported without Legislative Bureau amendments.

    4/29/2026House

  24. Reported with amendments (9-0). Referred to the Legislative Bureau.

    4/28/2026House

  25. Read by title, under the rules, referred to the Committee on Health and Welfare.

    4/21/2026House

Bill Text

Related Bills

Back to State Legislation